Meanwhile, PARPi activate the STING/TBK1/IRF3 pathway, resulting in increased expression of chemokines, such as the potent chemoattractants CXCL10 and CCL5, which target CD8+ T cells and enhance the immune response in the tumor microenvironment (Fig. 6) [220, 221]. This evidence concerns the gene IRF3 and neoplasm.